Wants to expand in France, Italy and Spain Says first listing possible in February (Adds InPost CEO comments)
WARSAW, Jan 13 (Reuters) - Polish parcel locker firm InPost plans an initial public offering (IPO) in Amsterdam and aims to debut on Euronext as early as February, it said, as it seeks to expand abroad to capitalise on a surge in online shopping.
Reuters reported in December that private equity firm Advent International was preparing an Amsterdam IPO for InPost that would value its equity at 7-8 billion euros ($8.5-$9.85 billion)
The business, widely used in Poland by sellers on online commerce platform Allegro, has benefited from an online boom as the COVID-19 pandemic keeps shoppers in their homes.
AbCellera closes record biotech IPO as underwriters exercise option to buy shares; total proceeds US$555.5-million Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
The Vancouver antibody developer – a key player in the fight against COVID-19 - said late Tuesday it had raised US$555.5-million in gross proceeds, more than double the prior record for a Canadian biotech IPO, by Montreal’s Repare Therapeutics Inc. in June.
The AbCellera offering had one of the biggest debuts of the year for any North American stock when it began trading Friday on the Nasdaq Stock Market, nearly tripling to close at US$58.90. It has since eased off, closing Tuesday at US$46.99 a share. That’s still well above its issue price and leaves the company with a market capitalization of $12.65-billion, more
A Canadian biotech giant is born: AbCellera stock triples in debut, company now worth US$15-billion Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
AbCellera/Courtesy of manufacturer
AbCellera Biologics Inc. (abcellera) had one of the most explosive debuts of any initial public offering this year as stock of the Vancouver antibody developer – a key player in the fight against COVID-19 – nearly tripled in value on its first day of trading on Friday.